PUBLISHER: SPER Market Research Pvt. Ltd. | PRODUCT CODE: 1089966
PUBLISHER: SPER Market Research Pvt. Ltd. | PRODUCT CODE: 1089966
According to SPER Market Research, the Molecular Biology Enzymes & Kits & Reagents Market estimated to reach USD 48.21 billion by 2030 with a CAGR of 13.6%. Amplified research, investments, increasing number of genome projects, technological advancement in the life science industry, and growing incidence of genetic disorders; are the fuels for the escalation of the market.
The outbreak of COVID-19 gives a positive impact to the expansion Molecular Biology Enzymes & Kits & Reagents Market.
The increasing numeral of genome projects globally, tied with dipping genetic analysis costs; leads to advancement in research in diverse fields like; personalized medicine, microbial genetic, disease treatment. This research need the use of molecular biology enzymes and reagents, consequently impel the expansion of this molecular biology enzymes and kits & reagents market.
The inflexible reimbursement policy is the restraints to this market.
Increase in the funds & grants from the government, advancement in the genomic technological facade, investments in research & development have vast opportunities for this market.
Based on the Product, Molecular Biology Enzymes & Kits & Reagents Market is segmented as; Kits & Reagents, Enzymes, Polymerases, Ligases, Restriction Endonucleases, Reverse Transcriptases, Other Enzymes.
Based on the Application, Molecular Biology Enzymes & Kits & Reagents Market is segmented as; PCR, Sequencing, Cloning, Epigenetics, Restriction Digestion, Synthetic Biology, Other Applications.
Based on the End-Users, Molecular Biology Enzymes & Kits & Reagents Market is segmented as; Academic & Research Institutes, Pharmaceutical & Biotechnology companies, Hospitals & Diagnostic Centers, Other End Users.
North America dominates the biggest share of this market; this is due to the increase in funding of translational and clinical research, increasing the figure of pharmaceutical and biotechnology companies, rising investments in research projects in Canada favourable reimbursement scenario.